CVRx, Inc. — Q1 2024 Form 10-Q
Period: Three months ended March 31, 2024; unaudited. Comparisons are with Q1 2023 unless otherwise noted. CVRx is a commercial-stage medical-device company whose principal product is Barostim, a neuromodulation device for heart failure and resistant hypertension.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $10.8 million | $8.0 million | Up 35% |
| Gross profit / margin | $9.2 million / 85% | $6.7 million / 83% | Margin up 2 percentage points |
| Operating expenses | $31.4 million | $18.8 million | Up 67% |
| Operating loss | $(22.2) million | $(12.2) million | Loss widened |
| Net loss | $(22.2) million | $(11.4) million | Loss widened 95% |
| Net loss per share | $(1.04) | $(0.55) | |
| Operating cash flow | $(10.9) million | $(10.2) million | Cash use increased |
- U.S. revenue was $9.8 million, up 42%; Europe revenue was $0.9 million, down 10%. U.S. heart-failure device units increased to 319 from 225; active implanting centers rose to 190 from 122.
- Cost of goods sold increased 22%, slower than revenue growth; management attributed the gross-margin improvement primarily to lower unit costs as production volume increased.
- SG&A rose 84% to $28.3 million, including a $9.6 million increase in non-cash stock-based compensation, higher compensation and travel costs. R&D fell 11% to $3.1 million.
- Q1 2024 included $8.4 million of non-cash stock-based compensation from modifying the former CEO’s options upon retirement. Total stock-based compensation was $11.1 million versus $1.7 million a year earlier.
Liquidity, debt and capital
- Cash and cash equivalents were $80.1 million at March 31, 2024, down from $90.6 million at year-end. Cash used in investing was $0.9 million; financing provided $1.4 million, mainly from option exercises and ATM share sales.
- Current assets were $102.3 million and current liabilities $8.4 million. The company reported total liabilities of $39.9 million and stockholders’ equity of $66.3 million.
- Term-loan principal outstanding was $30.0 million (carrying value $29.3 million). The debt bears a floating interest rate and is secured by substantially all personal property; interest-only payments run through November 2027, with principal maturities shown in 2027 and 2028. The company was compliant with loan covenants at quarter-end.
- An additional loan tranche of up to $20 million may be available in September–December 2024, subject to conditions including a trailing three-month revenue milestone. The company also has approximately $49.4 million of remaining capacity under its $50 million ATM program; Q1 ATM proceeds were $0.6 million.
- Management said existing cash, the loan agreement and revenue are expected to fund forecast operating liquidity, capital expenditures and debt service for at least three years. It cautioned that additional financing may be needed if those resources are insufficient.
Outlook, developments and risks
- No specific revenue or earnings guidance was provided. Management expects continued operating losses and negative operating cash flows for the foreseeable future, and significant losses for at least the next several years.
- Management cited U.S. commercial-force expansion, broader awareness and reimbursement, product development, and manufacturing efficiency as priorities. It estimates the U.S. annual market opportunity at $2.2 billion, or 76,000 patients, following expanded labeling and 2024 reimbursement changes.
- Effective January 1, 2024, Barostim received a new Medicare outpatient payment assignment with an average payment amount of $45,000. Coverage and payment remain subject to payer decisions, including case-by-case adjudication where formal coverage policies are absent.
- CEO Kevin Hykes took office in February, succeeding retiring CEO Nadim Yared. The company reported sales-organization turnover and lower February productivity, followed by stronger March performance after territory-rebuilding actions. It also announced the U.S. sales SVP’s termination effective April 29.
- In April, CVRx suspended enrollment in the BATwire clinical trial due to slow enrollment as eligible patients chose the commercially approved procedure; it plans to continue follow-up of enrolled patients.
- Key risks include continued losses and financing needs; dependence on Barostim and market acceptance; reimbursement uncertainty; competition; reliance on a limited supplier base; executive and sales-force retention; and the need for further long-term clinical data. Cash balances exceeded insured limits and were held primarily at two U.S. financial institutions. The filing reported no material legal proceedings or accrued contingent liabilities.
Important facts for investors to verify
- Whether U.S. revenue growth and expanded implant-center activity continue, and whether European sales stabilize.
- Whether the $45,000 payment assignment translates into payer coverage, hospital adoption and procedure volume.
- Whether the company meets the revenue condition for the potential $20 million loan tranche and remains compliant with debt covenants.
- How operating cash use, losses and share issuance under the ATM affect liquidity and dilution; also monitor the impact of substantial stock-based compensation.
- Progress in rebuilding the sales organization, filling planned leadership roles, and completing follow-up of the BATwire trial.